DRMA saw its Momentum Indicator move below the 0 level on October 08, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 97 similar instances where the indicator turned negative. In 93 of the 97 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for DRMA turned negative on October 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 54 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DRMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DRMA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DRMA's RSI Indicator exited the oversold zone, 34 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 70 cases where DRMA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
Following a +2.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where DRMA advanced for three days, in 152 of 193 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
DRMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.136) is normal, around the industry mean (2.988). P/E Ratio (-0.190) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. DRMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DRMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PVLA's RSI Oscillator exited the oversold zone, 20 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
Following a +2.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where PVLA advanced for three days, in 222 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
PVLA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PVLA as a result. In 86 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for PVLA turned negative on September 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 32 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
PVLA moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PVLA crossed bearishly below the 50-day moving average on September 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PVLA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for PVLA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.410) is normal, around the industry mean (2.988). P/E Ratio (-26.099) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. PVLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PVLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PVLA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 58 | |
P/E GROWTH RATING 1..100 | 42 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| DRMA | PVLA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| Advances ODDS (%) | 17 days ago 79% | 2 days ago 82% |
| Declines ODDS (%) | 4 days ago 90% | 9 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 87% | 2 days ago 83% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 87% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DRMA’s FA Score shows that 0 FA rating(s) are green while PVLA’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DRMA’s TA Score shows that 4 TA indicator(s) are bullish while PVLA’s TA Score has 4 bullish TA indicator(s).
DRMA (@Biotechnology) experienced а +27.72% price change this week, while PVLA (@Biotechnology) price change was +3.26% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
DRMA is expected to report earnings on Nov 13, 2026.
PVLA is expected to report earnings on Nov 10, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, DRMA has been loosely correlated with PVLA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if DRMA jumps, then PVLA could also see price increases.
| Ticker / NAME | Correlation To DRMA | 1D Price Change % | ||
|---|---|---|---|---|
| DRMA | 100% | -8.09% | ||
| PVLA - DRMA | 40% Loosely correlated | +2.15% | ||
| PLRX - DRMA | 32% Poorly correlated | -2.92% | ||
| KRRO - DRMA | 28% Poorly correlated | -1.59% | ||
| KALA - DRMA | 26% Poorly correlated | +0.58% | ||
| CRBP - DRMA | 26% Poorly correlated | -3.05% | ||
More | ||||
A.I.dvisor indicates that over the last year, PVLA has been loosely correlated with VIR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PVLA jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To PVLA | 1D Price Change % | ||
|---|---|---|---|---|
| PVLA | 100% | +2.15% | ||
| VIR - PVLA | 44% Loosely correlated | -1.58% | ||
| DRMA - PVLA | 42% Loosely correlated | -8.09% | ||
| DNTH - PVLA | 41% Loosely correlated | -0.83% | ||
| BEAM - PVLA | 41% Loosely correlated | -0.36% | ||
| EDIT - PVLA | 41% Loosely correlated | -2.71% | ||
More | ||||